AU2013237503B2 - Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease - Google Patents
Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- AU2013237503B2 AU2013237503B2 AU2013237503A AU2013237503A AU2013237503B2 AU 2013237503 B2 AU2013237503 B2 AU 2013237503B2 AU 2013237503 A AU2013237503 A AU 2013237503A AU 2013237503 A AU2013237503 A AU 2013237503A AU 2013237503 B2 AU2013237503 B2 AU 2013237503B2
- Authority
- AU
- Australia
- Prior art keywords
- pyrazol
- cyclopropyl
- amino
- cyanobenzoyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613187P | 2012-03-20 | 2012-03-20 | |
| US61/613,187 | 2012-03-20 | ||
| PCT/EP2013/055730 WO2013139809A1 (en) | 2012-03-20 | 2013-03-19 | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013237503A1 AU2013237503A1 (en) | 2014-09-25 |
| AU2013237503B2 true AU2013237503B2 (en) | 2016-05-26 |
Family
ID=47901996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013237503A Active AU2013237503B2 (en) | 2012-03-20 | 2013-03-19 | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9339491B2 (https=) |
| EP (1) | EP2827860B1 (https=) |
| JP (1) | JP6091593B2 (https=) |
| KR (1) | KR101793777B1 (https=) |
| CN (1) | CN104203234B (https=) |
| AU (1) | AU2013237503B2 (https=) |
| BR (1) | BR112014023107B1 (https=) |
| CA (1) | CA2866108C (https=) |
| CL (1) | CL2014002471A1 (https=) |
| CY (1) | CY1118327T1 (https=) |
| DK (1) | DK2827860T3 (https=) |
| ES (1) | ES2605942T3 (https=) |
| HR (1) | HRP20161514T1 (https=) |
| HU (1) | HUE032004T2 (https=) |
| IL (1) | IL234537A (https=) |
| LT (1) | LT2827860T (https=) |
| MA (1) | MA37455B1 (https=) |
| MX (1) | MX351996B (https=) |
| NZ (1) | NZ628392A (https=) |
| PH (1) | PH12014502107B1 (https=) |
| PL (1) | PL2827860T3 (https=) |
| PT (1) | PT2827860T (https=) |
| RU (1) | RU2625762C2 (https=) |
| SG (1) | SG11201404941WA (https=) |
| SI (1) | SI2827860T1 (https=) |
| TN (1) | TN2014000350A1 (https=) |
| TW (1) | TWI583381B (https=) |
| WO (1) | WO2013139809A1 (https=) |
| ZA (1) | ZA201405871B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600833C1 (ru) * | 2015-09-03 | 2016-10-27 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) | Способ лечения хронической обструктивной болезни легких |
| RU2600822C1 (ru) * | 2015-09-03 | 2016-10-27 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) | Способ лечения хронического обструктивного бронхита |
| KR102762199B1 (ko) * | 2016-03-08 | 2025-02-07 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 |
| BR112018067784A2 (pt) * | 2016-03-08 | 2019-01-15 | Mereo Biopharma 1 Ltd | regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias |
| US10331542B2 (en) * | 2016-06-23 | 2019-06-25 | International Business Machines Corporation | System and method for detecting and alerting unexpected behavior of software applications |
| GB201612238D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
| GB201612240D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP7280627B2 (ja) * | 2017-12-11 | 2023-05-24 | メレオ バイオファーマ １ リミテッド | 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用 |
| AU2018381874B2 (en) | 2017-12-11 | 2024-08-15 | Mereo Biopharma 1 Limited | Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease |
| CN114141383A (zh) * | 2021-12-17 | 2022-03-04 | 湖南大学 | 慢阻肺智能护理方法、装置及系统 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009973A1 (en) * | 2003-06-26 | 2005-02-03 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
| WO2007096151A2 (en) * | 2006-02-23 | 2007-08-30 | Novartis Ag | Inhibitors of p38-kinase for treatment of pulmonary hypertension |
-
2013
- 2013-03-19 WO PCT/EP2013/055730 patent/WO2013139809A1/en not_active Ceased
- 2013-03-19 HU HUE13710851A patent/HUE032004T2/en unknown
- 2013-03-19 DK DK13710851.0T patent/DK2827860T3/en active
- 2013-03-19 MA MA37455A patent/MA37455B1/fr unknown
- 2013-03-19 SI SI201330397A patent/SI2827860T1/sl unknown
- 2013-03-19 AU AU2013237503A patent/AU2013237503B2/en active Active
- 2013-03-19 PL PL13710851T patent/PL2827860T3/pl unknown
- 2013-03-19 BR BR112014023107-9A patent/BR112014023107B1/pt active IP Right Grant
- 2013-03-19 JP JP2015500892A patent/JP6091593B2/ja active Active
- 2013-03-19 ES ES13710851.0T patent/ES2605942T3/es active Active
- 2013-03-19 KR KR1020147025904A patent/KR101793777B1/ko active Active
- 2013-03-19 EP EP13710851.0A patent/EP2827860B1/en active Active
- 2013-03-19 MX MX2014011291A patent/MX351996B/es active IP Right Grant
- 2013-03-19 NZ NZ628392A patent/NZ628392A/en unknown
- 2013-03-19 CA CA2866108A patent/CA2866108C/en active Active
- 2013-03-19 CN CN201380015703.5A patent/CN104203234B/zh active Active
- 2013-03-19 SG SG11201404941WA patent/SG11201404941WA/en unknown
- 2013-03-19 LT LTEP13710851.0T patent/LT2827860T/lt unknown
- 2013-03-19 US US14/386,174 patent/US9339491B2/en active Active
- 2013-03-19 PT PT137108510T patent/PT2827860T/pt unknown
- 2013-03-19 TW TW102109739A patent/TWI583381B/zh active
- 2013-03-19 RU RU2014141893A patent/RU2625762C2/ru active
- 2013-03-19 HR HRP20161514TT patent/HRP20161514T1/hr unknown
-
2014
- 2014-08-11 ZA ZA2014/05871A patent/ZA201405871B/en unknown
- 2014-08-11 TN TNP2014000350A patent/TN2014000350A1/fr unknown
- 2014-09-08 IL IL234537A patent/IL234537A/en active IP Right Grant
- 2014-09-17 CL CL2014002471A patent/CL2014002471A1/es unknown
- 2014-09-22 PH PH12014502107A patent/PH12014502107B1/en unknown
-
2016
- 2016-04-29 US US15/143,356 patent/US20160243081A1/en not_active Abandoned
- 2016-11-18 CY CY20161101194T patent/CY1118327T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009973A1 (en) * | 2003-06-26 | 2005-02-03 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
| WO2007096151A2 (en) * | 2006-02-23 | 2007-08-30 | Novartis Ag | Inhibitors of p38-kinase for treatment of pulmonary hypertension |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013237503B2 (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| TWI730986B (zh) | 抗真菌化合物方法 | |
| EP3495362B1 (en) | Imidazopyridine thioglycolic acid derivative, preparation method therefor and application thereof | |
| JP2005511722A6 (ja) | Ｂｉｒｂ７９６ｂｓの投与方法 | |
| KR20150046110A (ko) | 피르페니돈 치료제의 투여 방법 | |
| EA200500096A1 (ru) | Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ | |
| JP2023517312A (ja) | ヒト免疫不全ウイルスの複製阻害剤 | |
| WO2023083847A1 (en) | Isoxazolidines as ripk1 inhibitors and use thereof | |
| US20150133423A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| WO2022053993A2 (en) | Treatments for sars-cov-2 infection (covid-19) | |
| HK1200352B (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| AU2022295130A1 (en) | COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | |
| EP3784349B1 (en) | Compounds with hiv maturation inhibitory activity | |
| US9745275B2 (en) | Pain-related compound and medical composition | |
| JP2025530668A (ja) | Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用 | |
| WO2025188857A8 (en) | Hdac8 degraders and uses thereof | |
| WO2023056463A1 (en) | Glycogen synthase kinase 3 (gsk3) inhibitors for treating ctnnb1 syndrome | |
| CN1985833A (zh) | 雌酚酮衍生物ea204在制备血管平滑肌松弛剂中的用途 | |
| JPH07206686A (ja) | 感染疾患の予防または治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: MEREO BIOPHARMA 1 LIMITED Free format text: FORMER APPLICANT(S): NOVARTIS AG |
|
| FGA | Letters patent sealed or granted (standard patent) |